{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:48:00Z","timestamp":1782910080457,"version":"3.54.5"},"reference-count":21,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Cladribine is a high-efficacy immune reconstitution therapy for relapsing multiple sclerosis, but additional real-world data remain valuable, particularly from single-center cohorts with combined clinical, radiological, and laboratory follow-up. This study aimed to evaluate the 24-month effectiveness and safety of cladribine in patients with relapsing-remitting multiple sclerosis (RRMS), with a particular focus on no evidence of disease activity (NEDA-3) and lymphopenia. Methods: This retrospective single-center observational cohort study included adults with RRMS treated with cladribine who had at least 24 months of clinical and MRI follow-up. NEDA-3 was defined as the absence of clinical relapses, disability progression, and MRI activity. Brain MRI was performed at 6, 12, and 24 months. Absolute lymphocyte counts were monitored longitudinally, and lymphopenia was graded according to standard criteria. Results: A total of 71 patients were included. NEDA-3 was achieved in 61 patients (85.9%) at 12 months and 50 patients (70.4%) at 24 months. No demographic or baseline clinical variable was independently associated with NEDA-3 at either time point. Lymphopenia occurred in 53 patients (74.6%), including grade 1 in 14 (19.7%), grade 2 in 23 (32.4%), grade 3 in 14 (19.7%), and grade 4 in 2 (2.8%). One patient developed herpes zoster infection during follow-up. Conclusions: Cladribine demonstrated durable effectiveness and a manageable safety profile over 24 months in a real-world RRMS population. The close alignment between our findings and those reported in pivotal clinical trials underscores the external validity of cladribine efficacy beyond controlled study environments. These data provide valuable real-world evidence bridging the gap between controlled research settings and everyday patient care, thereby strengthening the evidence base for cladribine in contemporary MS management.<\/jats:p>","DOI":"10.3390\/jcm15135121","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:41:01Z","timestamp":1782902461000},"page":"5121","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing\u2014Remitting Multiple Sclerosis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3723-6335","authenticated-orcid":false,"given":"Duygu \u00d6zkan","family":"Ya\u015farg\u00fcn","sequence":"first","affiliation":[{"name":"Department of Neurology, Haydarpa\u015fa Numune Training and Research Hospital, University of Health Sciences, \u0130stanbul 34668, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recai","family":"T\u00fcrko\u011flu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Haydarpa\u015fa Numune Training and Research Hospital, University of Health Sciences, \u0130stanbul 34668, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0140-6736(16)30959-X","article-title":"Diagnosis of multiple sclerosis: Progress and challenges","volume":"389","author":"Brownlee","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17562864251342855","DOI":"10.1177\/17562864251342855","article-title":"Cladribine tablets in the new multiple sclerosis era","volume":"18","author":"Buttari","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Correale, J., Marrodan, M., and Ysrraelit, M.C. (2019). Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis. Biomedicines, 7.","DOI":"10.3390\/biomedicines7010014"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104735","DOI":"10.1016\/j.msard.2023.104735","article-title":"Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort","volume":"75","author":"Aerts","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"CLARITY Study Group. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458518771875","article-title":"Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study","volume":"25","author":"Giovannoni","year":"2019","journal-title":"Mult. Scler. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: An ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult. Scler. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11795735241262743","DOI":"10.1177\/11795735241262743","article-title":"Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry","volume":"16","author":"Potuznik","year":"2024","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104491","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","article-title":"MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study","volume":"260","author":"Comi","year":"2013","journal-title":"J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1756285617753365","DOI":"10.1177\/1756285617753365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: The CLARITY Extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2174\/1570159X21666230322140711","article-title":"Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study)","volume":"22","author":"Arena","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108615","DOI":"10.1016\/j.clineuro.2024.108615","article-title":"Real world experience with cladribine tablets in the management of relapsing multiple sclerosis in Qatar","volume":"247","author":"Canibano","year":"2024","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult. Scler. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10354-022-00931-4","article-title":"Real-world evidence for cladribine tablets in multiple sclerosis: Further insights into efficacy and safety","volume":"172","author":"Moser","year":"2022","journal-title":"Wien. Med. Wochenschr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple Sclerosis Severity Score: Using Disability and Disease Duration to Rate Disease Severity","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","article-title":"Predictors of cladribine effectiveness and safety in multiple sclerosis: A real-world, multicenter, 2-year follow-up study","volume":"11","author":"Petracca","year":"2022","journal-title":"Neurol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5121\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:06:01Z","timestamp":1782907561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":21,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135121"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135121","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}